Germline DNA Copy Number Aberrations Identified as Potential Prognostic Factors for Breast Cancer Recurrence

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Sapkota, Yadav ^a,b   Ghosh, Sunita ^a,b   Lai, Raymond ^a,b   Coe, Bradley P ^c   Cass, Carol E ^a,b   Yasui, Yutaka ^b   Mackey, John R ^a,b   Damaraju, Sambasivarao ^a,b  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DNA; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME 6Q; COPY NUMBER VARIATION; FEMALE; GENE DOSAGE; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; PHENOTYPE; PROGNOSIS; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN; DNA COPY NUMBER VARIATIONS; FEMALE; GENOTYPING TECHNIQUES; HETEROZYGOTE; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVUM; PROGNOSIS; RECURRENCE;

EID: 84872484694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053850     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Canadian Cancer Society's Steering Committee on Cancer Statistics (2011) Canadian Cancer Statistics 2011. Toronto, ON: Canadian Cancer Society.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365: 1687-1717.
4. Weigel MT, Dowsett M, (2010) Current and emerging biomarkers in breast cancer: Prognosis and prediction.EndocrRelat Cancer. 17: R245-62.
5. van der Leij F, Elkhuizen PH, Bartelink H, van de VijverMJ, (2012) Predictive factors for local recurrence in breast cancer. SeminRadiatOncol 22: 100-107.
6. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
7. van de VijverMJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
8. Gonzalez-AnguloAM, Morales-Vasquez F, Hortobagyi GN, (2007) Overview of resistance to systemic therapy in patients with breast cancer.AdvExp Med Biol. 608: 1-22.
9. VoducKD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, et al. (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28: 1684-1691.
10. Sapkota Y, Robson P, Lai R, Cass CE, Mackey JR, et al. (2012) A two-stage association study identifies methyl-CpG-binding domain protein 2 gene polymorphisms as candidates for breast cancer susceptibility. Eur J Hum Genet 20: 682-689.
11. Sehrawat B, Sridharan M, Ghosh S, Robson P, Cass CE, et al. (2011) Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility. Hum Genet 130: 529-537.
12. Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, et al. (2012) Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 44: 312-318.
13. Shu XO, Long J, Lu W, Li C, Chen WY, et al. (2012) Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res 72: 1182-1189.
14. Martin DN, Boersma BJ, Howe TM, Goodman JE, Mechanic LE, et al. (2006) Association of MTHFR gene polymorphisms with breast cancer survival. BMC Cancer 6: 257.
15. Lin WY, Camp NJ, Cannon-Albright LA, Allen-Brady K, Balasubramanian S, et al. (2011) A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J Med Genet 48: 477-484.
16. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, et al. (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 102: 1003-1009.
17. Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, et al. (2010) Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 70: 319-328.
18. Easton DF, Pooley KA, Dunning AM, PharoahPD, Thompson D, et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093.
19. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, et al. (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40: 703-706.
20. Krepischi AC, Achatz MI, Santos EM, Costa SS, Lisboa BC, et al. (2012) Germline DNA copy number variation in familial and early-onset breast cancer. Breast Cancer Res 14: R24.
21. Kuiper RP, LigtenbergMJ, Hoogerbrugge N, Geurts van Kessel A, (2010) Germline copy number variation and cancer risk. CurrOpin Genet Dev 20: 282-289.
22. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, et al. (2006) Global variation in copy number in the human genome. Nature 444: 444-454.
23. Wellcome Trust Case Control Consortium, Craddock N, Hurles ME, Cardin N, Pearson RD, et al. (2010) Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature 464: 713-720.
24. Yoshihara K, Tajima A, Adachi S, Quan J, Sekine M, et al. (2011) Germline copy number variations in BRCA1-associated ovarian cancer patients. Genes Chromosomes Cancer 50: 167-177.
25. HenrichsenCN, Chaignat E, Reymond A, (2009) Copy number variants, diseases and gene expression. Hum Mol Genet 18: R1-8.
26. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, et al. (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315: 848-853.
27. Melcher R, Hartmann E, Zopf W, Herterich S, Wilke P, et al. (2011) LOH and copy neutral LOH (cnLOH) act as alternative mechanism in sporadic colorectal cancers with chromosomal and microsatellite instability. Carcinogenesis 32: 636-642.
28. Saeki H, Kitao H, Yoshinaga K, Nakanoko T, Kubo N, et al. (2011) Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clin Cancer Res 17: 1731-1740.
29. Kryh H, Caren H, Erichsen J, SjobergRM, Abrahamsson J, et al. (2011) Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics 12: 443.
30. Makishima H, Maciejewski JP, (2011) Pathogenesis and consequences of uniparental disomy in cancer.Clin Cancer Res. 17: 3913-3923.
31. Lapunzina P, Monk D, (2011) The consequences of uniparental disomy and copy number neutral loss-of-heterozygosity during human development and cancer. Biol Cell 103: 303-317.
32. O'Keefe C, McDevitt MA, Maciejewski JP, (2010) Copy neutral loss of heterozygosity: A novel chromosomal lesion in myeloid malignancies. Blood 115: 2731-2739.
33. Mohamedali A, Gaken J, Twine NA, Ingram W, Westwood N, et al. (2007) Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110: 3365-3373.
34. Bernstein L, Lacey JV Jr, (2011) Receptors, associations, and risk factor differences by breast cancer subtypes: Positive or negative? J Natl Cancer Inst 103: 451-453.
35. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391.
36. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
37. Shlien A, Malkin D, (2010) Copy number variations and cancer susceptibility. CurrOpinOncol 22: 55-63.
38. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289-300.
39. Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, et al. (2001) Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. ProcNatlAcadSci U S A 98: 6348-6353.
40. Reynolds PA, Sigaroudinia M, Zardo G, Wilson MB, Benton GM, et al. (2006) Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J BiolChem 281: 24790-24802.
41. Zickler AM, Hampp S, Messiaen L, Bengesser K, Mussotter T, et al. (2012) Characterization of the nonallelic homologous recombination hotspot PRS3 associated with type-3 NF1 deletions. Hum Mutat 33: 372-383.
42. Nakajima T, Kaur G, Mehra N, Kimura A, (2008) HIV-1/AIDS susceptibility and copy number variation in CCL3L1, a gene encoding a natural ligand for HIV-1 co-receptor CCR5. Cytogenet Genome Res 123: 156-160.
43. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, et al. (2012) A refined molecular taxonomy of breast cancer. Oncogene 31: 1196-1206.
44. Grube M, Reuther S, Meyer ZuSchwabedissen H, Kock K, Draber K, et al. (2007) Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metabolism & Disposition 35: 30-35.
45. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 395-399.